JP2012515213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515213A5 JP2012515213A5 JP2011546329A JP2011546329A JP2012515213A5 JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5 JP 2011546329 A JP2011546329 A JP 2011546329A JP 2011546329 A JP2011546329 A JP 2011546329A JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- individual
- combination
- antigen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 11
- 102000038129 antigens Human genes 0.000 claims 11
- 108091007172 antigens Proteins 0.000 claims 11
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 6
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 229940117681 Interleukin-12 Drugs 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QFJCIRLUMZQUOT-SWBOGZMGSA-N Rapamune Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-SWBOGZMGSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (15)
- ＣＤ８＋Ｔ細胞の個体群及び哺乳類ラパマイシン標的タンパク質（ｍＴＯＲ）阻害剤を含む組成物。
- 前記ＣＤ８＋Ｔ細胞が前記組成物の細胞中に少なくとも１０％含まれる、請求項１に記載の組成物。
- 前記ＣＤ８＋Ｔ細胞が特異的で、かつ、個体において免疫応答の増強が所望される抗原をさらに含む、請求項１に記載の組成物。
- さらにインターロイキン１２（ＩＬ−１２）を含む、請求項３に記載の組成物。
- 抗原が腫瘍抗原である、請求項３に記載の組成物。
- 個体において、抗原に対する増強された免疫応答を得るための組み合わせであって、前記抗原及び哺乳類ラパマイシン標的タンパク質（ｍＴＯＲ）阻害剤を含み、前記個体に前記抗原及び哺乳類ラパマイシン標的タンパク質（ｍＴＯＲ）阻害剤が投与される、組み合わせ。
- 前記組み合わせががんワクチン療法に用いられる組み合わせであり、前記個体が、がんを有すると診断されもしくは疑われており、前記がんが前記抗原を発現しているがん細胞を含む、請求項６に記載の組み合わせ。
- 個体において、前記抗原の投与に続いて前記ｍＴＯＲ阻害剤が投与される、請求項６又は７に記載の組み合わせ。
- 少なくとも７日間、少なくとも１日１回、ｍＴＯＲ阻害剤が個体に投与される、請求項８に記載の組み合わせ。
- 継続して２０日間を超えない期間、ｍＴＯＲ阻害剤が個体に投与される、請求項８に記載の組み合わせ。
- ｍＴＯＲ阻害剤が、ラパマイシン又はテムシロリムスである、請求項６に記載の組み合わせ。
- さらに、前記抗原に特異的なＣＤ８＋Ｔ細胞を含む組成物を含み、個体において、前記抗原に特異的なＣＤ８＋Ｔ細胞を含む組成物を投与することを含む、請求項６に記載の組み合わせ。
- 個体にＣＤ８＋Ｔ細胞を投与する以前に、前記抗原がＣＤ８＋Ｔ細胞に提示されている、請求項１２に記載の組み合わせ。
- 個体にＣＤ８＋Ｔ細胞を投与する以前に、ＣＤ８＋Ｔ細胞がｍＴＯＲ阻害剤と接触させられている、請求項１３に記載の組み合わせ。
- 個体にＣＤ８＋Ｔ細胞を含む前記組成物を投与する以前に、個体からＣＤ８＋Ｔ細胞が単離されている、請求項１２に記載の組み合わせ。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14453709P | 2009-01-14 | 2009-01-14 | |
| US61/144,537 | 2009-01-14 | ||
| US29309610P | 2010-01-07 | 2010-01-07 | |
| US61/293,096 | 2010-01-07 | ||
| PCT/US2010/021029 WO2010083298A1 (en) | 2009-01-14 | 2010-01-14 | Methods and compositions containing mtor inhibitors for enhancing immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515213A JP2012515213A (ja) | 2012-07-05 |
| JP2012515213A5 true JP2012515213A5 (ja) | 2012-12-27 |
Family
ID=42340082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546329A Pending JP2012515213A (ja) | 2009-01-14 | 2010-01-14 | 免疫応答を増強するための、ｍＴＯＲ阻害剤を含有する方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100196311A1 (ja) |
| EP (1) | EP2375897A4 (ja) |
| JP (1) | JP2012515213A (ja) |
| CN (1) | CN102281761A (ja) |
| CA (1) | CA2748931A1 (ja) |
| WO (1) | WO2010083298A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| CN105899232A (zh) | 2013-11-13 | 2016-08-24 | 诺华股份有限公司 | 用于增强免疫应答的mTOR抑制剂 |
| US11213583B2 (en) | 2014-02-05 | 2022-01-04 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
| CA2955465A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| AU2016263176A1 (en) | 2015-05-20 | 2017-12-07 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| PL3313401T3 (pl) | 2015-06-29 | 2022-02-07 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych |
| WO2017004266A1 (en) * | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| CA2992991A1 (en) | 2015-07-20 | 2017-01-26 | Mayo Foundation For Medical Education And Research | Methods and materials for producing t cells |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| US11096964B2 (en) * | 2016-01-20 | 2021-08-24 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| BR112019010470A2 (pt) | 2016-11-23 | 2019-09-10 | Novartis Ag | métodos de realce de resposta imune com everolimo, dactolisib ou ambos |
| EP3548049A4 (en) | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMMUNELL CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| MX2020013443A (es) | 2018-06-13 | 2021-02-26 | Novartis Ag | Receptores de antigeno quimerico de bcma y usos de los mismos. |
| CN110412289B (zh) * | 2019-07-25 | 2022-08-02 | 北京美迪阿姆科技发展有限公司 | 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用 |
| CN114426952A (zh) * | 2020-10-29 | 2022-05-03 | 中国科学技术大学 | 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999048524A1 (en) * | 1998-03-03 | 1999-09-30 | University Of Southern California | Use of cytokines and mitogens to inhibit graft versus host disease |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7718196B2 (en) * | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| WO2005003335A2 (en) * | 2003-06-12 | 2005-01-13 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rapamycin resistant t cells and therapeutic uses thereof |
| WO2003038062A2 (en) * | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
| US20060094674A1 (en) * | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| ATE353954T1 (de) * | 2002-10-11 | 2007-03-15 | Sentoclone Therapeutics Ab | Immuntherapie für krebs |
| KR20140019032A (ko) * | 2006-04-05 | 2014-02-13 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| US8119772B2 (en) * | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| US8765462B2 (en) * | 2007-05-04 | 2014-07-01 | University Health Network | IL-12 immunotherapy for cancer |
| AU2009279661A1 (en) * | 2008-08-05 | 2010-02-11 | Emory University | Use of mTOR inhibitors to enhance T cell immune responses |
-
2010
- 2010-01-14 JP JP2011546329A patent/JP2012515213A/ja active Pending
- 2010-01-14 CA CA2748931A patent/CA2748931A1/en not_active Abandoned
- 2010-01-14 US US12/687,650 patent/US20100196311A1/en not_active Abandoned
- 2010-01-14 EP EP10732083.0A patent/EP2375897A4/en not_active Withdrawn
- 2010-01-14 CN CN2010800048759A patent/CN102281761A/zh active Pending
- 2010-01-14 WO PCT/US2010/021029 patent/WO2010083298A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515213A5 (ja) | ||
| Legoux et al. | MAIT cell development and functions: the microbial connection | |
| Liu et al. | Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond | |
| US9730967B2 (en) | Method and system for treating cancer cachexia | |
| Wang et al. | Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy | |
| Sainathan et al. | Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis | |
| JP2015134813A5 (ja) | ||
| Yang et al. | Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment | |
| Roh et al. | Depletion of Foxp3+ regulatory T cells promotes profibrogenic milieu of cholestasis-induced liver injury | |
| US20200323905A1 (en) | Methods and compositions for modulating the immune system | |
| Pai et al. | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels | |
| JP2013541010A5 (ja) | ||
| Wu et al. | Matrine ameliorates spontaneously developed colitis in interleukin-10-deficient mice | |
| Hu et al. | Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice | |
| Dokmeci et al. | The immune system and atopic dermatitis | |
| Radhakrishnan et al. | Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation | |
| US20160067272A1 (en) | Methods for treating immune diseases | |
| Huart et al. | Could protons and carbon ions be the silver bullets against pancreatic cancer? | |
| Rawat et al. | The CD200-CD200R cross-talk helps Leishmania donovani to down regulate macrophage and CD4+ CD44+ T cells effector functions in an NFκB independent manner | |
| Qi et al. | P. aeruginosa mediated necroptosis in mouse tumor cells induces long-lasting systemic antitumor immunity | |
| Chen et al. | Irradiated whole‑cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells | |
| Viúdez-Pareja et al. | Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment | |
| Hu et al. | Beneficial effects of dual TORC1/2 inhibition on chronic experimental colitis | |
| Callejas et al. | Interleukin-4 programmed macrophages suppress colitis and do not enhance infectious-colitis, inflammation-associated colon cancer or airway hypersensitivity | |
| Zhang et al. | An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions |